Anavex Life Sciences Corp (AVXL)

[makemydaze]

Biogen had 2 phase 2 trials running for Opicinumab. The trial regarding MS failed to meet its endpoint -

"Today Biogen (NASDAQ: BIIB) reported top-line results from the Phase 2 SYNERGY study evaluating opicinumab (anti-LINGO-1), an investigational, fully human monoclonal antibody being developed as a potential neuroreparative therapy in people with relapsing forms of multiple sclerosis (RMS). In the study, opicinumab missed the primary endpoint, a multicomponent measure evaluating improvement of physical function, cognitive function, and disability."

I believe the other trial codenamed "RENEW" is still alive.

http://media.biogen.com/press-release/investor-relations/biogen-reports-top-line-results-phase-2-study-opicinumab-anti-lingo

The failure in the SYNERGY trial might have accelerated BIIB's interest in 2-73.

"Biogen witnessed a fall of about 12.7% in its share price as its stock closed at $252.86 after the release of the trial results. This underlined the expectations of the investor community related to the contribution of the anti-LINGO research program to Biogen’s future growth."